| Menorrhagia
Liletta vs Myfembree
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Liletta vs Myfembree with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMyfembree has a higher rate of injection site reactions vs Liletta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Myfembree but not Liletta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Liletta
Myfembree
At A Glance
Intrauterine
Single insertion
Progestin-releasing IUS
Oral
Daily
GnRH receptor antagonist
Indications
- Menorrhagia
- Uterine Fibroids
- Menorrhagia
- Endometriosis
Dosing
Contraception Single intrauterine insertion; remove by end of eighth year; may be replaced at time of removal for continued contraception.
Menorrhagia Single intrauterine insertion; replace by end of fifth year if continued treatment of heavy menstrual bleeding is needed.
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Contraindications
- Pregnancy
- Use as post-coital contraception (emergency contraception)
- Congenital or acquired uterine anomaly, including leiomyomas, that distorts the uterine cavity
- Acute pelvic inflammatory disease (PID)
- Postpartum endometritis or infected abortion in the past 3 months
- Known or suspected uterine or cervical malignancy
- Known or suspected breast cancer or other hormone-sensitive cancer, now or in the past
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis, including bacterial vaginosis, chlamydial or gonococcal cervical infection, or other lower genital tract infections until infection is controlled
- Acute liver disease or liver tumor (benign or malignant)
- Conditions associated with increased susceptibility to pelvic infections
- A previously inserted IUS that has not been removed
- History of hypersensitivity reaction to any component of LILETTA
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
Adverse Reactions
Most common (>=5%) Vulvovaginal mycotic infections, vaginal bacterial infections, acne, nausea or vomiting, headache, breast tenderness or pain, abdominal discomfort or pain, dyspareunia, anxiety, depression, pelvic discomfort or pain, dysmenorrhea, mood changes, back pain, weight increased, vaginal discharge
Serious Ectopic pregnancy, ovarian cysts, IUS perforation requiring laparoscopic surgery
Postmarketing Arterial thrombotic and venous thromboembolic events (pulmonary emboli, deep vein thrombosis, stroke), hypersensitivity reactions (rash, urticaria, angioedema), increased blood pressure, dizziness, device breakage
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Pharmacology
Levonorgestrel-releasing intrauterine system; locally released LNG prevents pregnancy by thickening cervical mucus to inhibit sperm passage, inhibiting sperm mobility and capacitation, and altering the endometrium.
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Liletta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
UnitedHealthcare
Liletta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Liletta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Liletta.
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LilettaView full Liletta profile
MyfembreeView full Myfembree profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.